Skip to main content Start of content

HESA Committee Meeting

Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Minutes of Proceedings

42nd Parliament, 1st Session
Meeting No. 6
Wednesday, April 13, 2016, 3:43 p.m. to 6:05 p.m.
Presiding
Bill Casey, Chair (Liberal)

Library of Parliament
• Karin Phillips, Analyst
• Marlisa Tiedemann, Analyst
Patented Medicine Prices Review Board
• Guillaume Couillard, Director, Board Secretariat, Communications and Strategic Planning
• Tanya Potashnik, Director, Policy and Economic Analysis Branch
Canadian Institute for Health Information
• Brent Diverty, Vice President, Programs
• Michael Gaucher, Director, Pharmaceuticals and Health Workforce Information Services
Department of Health
• Abby Hoffman, Assistant Deputy Minister, Strategic Policy Branch
• Scott Doidge, Director General, Non-Insured Health Benefits, First Nations and Inuit Health Branch
• Frances Hall, Director, Office of Pharmaceuticals Management Strategies, Strategic Policy Branch
Canadian Agency for Drugs and Technologies in Health
• Brian O'Rourke, President and Chief Executive Officer
Pursuant to Standing Order 108(2) and the motion adopted by the Committee on March 7, 2016, the Committee commenced its study of the Development of a National Pharmacare Program.

Abby Hoffman, Brent Diverty, Tanya Potashnik and Brian O'Rourke made statements and, with Michael Gaucher, answered questions.

At 5:31 p.m., the sitting was suspended.

At 5:38 p.m., the sitting resumed in camera.

The Committee proceeded to the consideration of matters related to Committee business.

It was agreed, — That the current practice of allowing witnesses to make opening statement of up to ten minutes be maintained for future meetings on the development of a national Pharmacare program.

It was agreed, — That a proposed budget in the amount of $ 29,700.00, for the study on the Development of a National Pharmacare Program, be adopted.

It was agreed, — That the draft work plan for the study on the Development of a National Pharmacare Program be adopted.

At 6:05 p.m., the Committee adjourned to the call of the Chair.



David Gagnon
Clerk of the Committee